Prescription ·Strong evidence ·Reviewed May 2026
Galantamine is a cholinesterase inhibitor used for mild to moderate Alzheimer disease dementia. It increases cholinergic signaling and also modulates nicotinic acetylcholine receptors, producing modest symptomatic benefit in some patients. Major tolerability concerns are gastrointestinal effects, weight loss, bradycardia, syncope, falls, and caution in seizure, pulmonary, urinary, or ulcer disease.
The bottom line
Evidence rating strong. Most-documented uses: symptomatic treatment of mild to moderate alzheimer disease dementia, potential stabilization or modest improvement in cognition, function, or global assessment, once-daily extended-release option. 3 sources indexed (2000–2026), with 4 interaction records on file.
Core mechanism
Galantamine reversibly inhibits acetylcholinesterase, increasing acetylcholine in synaptic spaces, and allosterically modulates nicotinic acetylcholine receptors. These actions may enhance cholinergic neurotransmission in brain regions affected by Alzheimer disease. Peripheral cholinergic effects explain nausea, vomiting, diarrhea, bradycardia, syncope, bronchoconstriction risk, urinary effects, and increased gastric acid secretion.2,3
Taking with food improves gastrointestinal tolerability. Maintain hydration during titration because vomiting or diarrhea can cause dehydration.
Ginkgo is sometimes used for cognition but may increase bleeding risk and has seizure case reports. Galantamine is used in a population vulnerable to falls and neurologic adverse effects.
Recommendation: Avoid unsupervised combination; review bleeding risk, seizure history, and fall risk with the clinician.
Magnesium can loosen stools, while galantamine commonly causes nausea, vomiting, and diarrhea.
Recommendation: Use cautiously if GI adverse effects, dehydration, poor intake, or weight loss occur.
Melatonin can add sedation, vivid dreams, or nighttime confusion in dementia patients taking galantamine.
Recommendation: Use cautiously and monitor falls, confusion, and morning sedation.
St. John's Wort induces CYP3A4 and may lower exposure to drugs with CYP3A4 metabolism, including galantamine.
Recommendation: Avoid unless the prescriber reviews the interaction and monitors cognitive or functional response.
Numbered references. Citations throughout the page link here.
Systematic review supports modest symptomatic benefit across cholinesterase inhibitors and documents adverse-effect burden.
Trial evidence supports symptomatic cognitive and global benefits with cholinergic adverse effects.
Labeling describes dosing, titration, bradycardia/AV block warning, GI adverse effects, and CYP2D6/CYP3A4 interaction considerations.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
